Pemetrexed for the treatment of non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 11, 2013, Pages 1545-1558

  Genova, Carlo ^a   Rijavec, Erika ^a   Truini, Anna ^a   Coco, Simona ^a   Sini, Claudio ^a   Barletta, Giulia ^a   Dal Bello, Maria Giovanna ^a   Alama, Angela ^a   Savarino, Grazia ^a   Pronzato, Paolo ^a   Boccardo, Francesco ^a,b   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemotherapy; Non small cell lung cancer; Pemetrexed; Thymidylate synthase

Indexed keywords

ACETYLSALICYLIC ACID; AFATINIB; BEVACIZUMAB; BILIRUBIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; ENZASTAURIN; FOLIC ACID; GEMCITABINE; MATUZUMAB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; STEROID; VANDETANIB;

ADJUVANT THERAPY; ADVANCED CANCER; ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DIARRHEA; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; ECONOMIC EVALUATION; FEBRILE NEUTROPENIA; GLOMERULUS FILTRATION; HEALTH CARE QUALITY; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; SIDE EFFECT; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 84880122419     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.802774     Document Type: Article

References (84)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. CA Cancer J Clin 2010;60(5):277-300 Available from: http://www.accessdata. fda.gov/drugsatfda- docs/label/2012/021462s039lbl.pdf
2. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat 2012;15(4):183-210
3. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007;6(2):404-17
4. Racanelli AC, Rothbart SB, Heyer CL, et al. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009;69(13):5467-674
5. Ceppi P, Rapa I, Lo Iacono M, et al. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. Int J Cancer 2012;130(8):1777-86
6. Igawa S, Ryuge S, Wada M, et al. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression. Chemotherapy 2012;58:313-20
7. Lustgarten DE, Deshpande C, Aggaewal C, et al. Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma. J Thorac Oncol 2013;8(4):469-77
8. Yang TY, Chang GC, Chen KC, et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through ataxia telangiectasia mutated/p53-dependent and-independent signaling pathways. Mol Carcinog 2013;52(3):183-94
9. Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011;7(7):919-28
10. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1(7):545-52
11. Richards DA, Socinski M, Raju RN, et al. The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small cell lung cancer (SCLC). J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 2007;25:7726
12. NCCN Clinical practice guidelines in oncology: antiemesis. Version 1.2013. Available from: http://www.nccn.org/professionals/physician-gls/pdf/ antiemesis.pdf [Access on 02 June 2013]
13. Dickgreber NJ, Sorensen JB, Paz-Ares LG, et al. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res 2010;16(10):2872-80
14. NCCN Clinical practice guidelines in oncology: non-small cell lung cancer. Version 2.2013. Available from: http://www.nccn.org/professionals/ physician-gls/pdf/nscl.pdf [Access on 02 June 2013]
15. Rusthoven JJ, Eisenhauer E, Butts C. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17(4):1194
16. Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-näve patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13(5):737-41
17. Manegold C, Gatzmeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 2000;11(4):435-40
18. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92(3):595-600
19. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 2005;104(11):2449-56
20. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11(2 Pt 1):690-6
21. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
22. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-96
23. Sigmond J, Backus HH, Wouters D, et al. Induction of resistance to the multitarget antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003;66:431-8
24. European public assessment report (EPAR) for Alimta. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/ 000564/WC500025611.pdf
25. Grønberg BH, Bremnes RM, Fløtten O, et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009;27(19):3217-24
26. Rodriguez-Pereira J, Kim JH, Magallanes M, et al. A randomized phase III trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6(11):1907-14
27. Yang JC, Schuler MH, Yamamoto N, et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012;30(Suppl):abstract LBA7500
28. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherpy for advanced NSCLC: maintenance treatment or early secondline? Oncologist 2009;14(2):137-47
29. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374(9699):1432-40
30. Belani CP, Brodowics T, Ciuleanu T, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a randomized phase III study in advanced non-small cell lung cancer [abstract CRA8000]. J Clin Oncol 2009;27(Suppl):18s
31. Gridelli C, De Marinis F, Di Maio M, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2012;76(3):269-79
32. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012;13(3):247-55
33. Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced non-squamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):abstract LBA7507
34. Barlesi F, de Castro J, Dvornichenko V, et al. AVAPERL (MO22089): final efficacy outcomes for patients with advanced non-squamous non-small cell lung cancer randomised to continuation maintenance with bevacizumab or bevacizumab + pemetrexed after first-line bevacizumab-cisplatin-pemetrexed treatment. In: Presented at 2011 ECCO-ESMO European Multidisciplinary Cancer Congress. Eur J Cancer 2011;47(Suppl):abstract 34LBA
35. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer. J Clin Oncol 2009;27(20):3284-9
36. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/ bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10(4):252-6
37. Patel J, Socinski MA, Garon EB, et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem) +carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous nonsmall cell lung cancer (NS-NSCLC). 2012 ASCO Multidisciplinary Symposium in Thoracic Oncology; 6-8 September 2012; Chicago
38. Tan EH, Havel L, Krzakowski MJ, et al. Randomized phase II trial of oral vinorelbine (N) and cisplatin (P) or pemetrexed and C (PC) in first line advanced non squamous (NSCLC) patients (PTS). NAVOTRIAL01: final results. Ann Oncol 2012;23(Suppl 9):abstract 1247p
39. Grossi F. Management of non-small cell lung cancer patients with stable disease. Drugs 2012;72(Suppl 1):20-7
40. Smit EF, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study. Ann Oncol 2003;14(3):455-60
41. Russo F, Bearz A, Pampaloni G, et al. Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer. BMC Cancer 2008;8:216
42. Hanna N, Sheperd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22(9):1589-97
43. Pujol JL, Paul S, Chouaki N, et al. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis. J Thorac Oncol 2007;2(5):397-401
44. Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) [abstract]. 12th World Conference on Lung Cancer. P2-328. J Thorac Oncol 2007;2(8):S851
45. Bearz A, Garassino I, Cavina R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-istitutional observational study. Lung Cancer 2008;60(2):240-5
46. Cullen MH, Zatloukal P, Sorenson S, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 2008;19(5):939-45
47. Ohe Y, Ichinose Y, Nakagawa K, et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 2008;14(13):4206-12
48. Kim HS, Lee GW, Kim JH, et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer 2010;70(1):71-6
49. Zhang GZ, Jiao SC, Meng TZ. Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients. J Exp Clin Cancer Res 2010;29:38
50. Lee DH, Choi CM, Kim SW, et al. Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients. Med Oncol 2012;29(2):640-3
51. Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27(12):2038-45
52. Ardizzoni A, Tiseo M, Boni L, et al. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. J Clin Oncol 2012;30(36):4501-7
53. Karapanagiotou EM, Boura PG, Papamichalis G, et al. Carboplatin- pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res 2009;29(10):4297-301
54. Schmid-Bindert G, Chemaissani A, Fischer JR, et al. Pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in early-stage NSCLC [abstract 7565]. J Clin Oncol 2009;15s(Suppl):27
55. Kreuter M, Vansteenkiste J, Fischer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Ann Oncol 2013;24(3):986-92
56. Pemetrexed and cisplatin treatment before surgery in non small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00259285
57. Pemetrexed disodium and cisplatin in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00248495
58. Neoadjuvant platinum-based chemotherapy for patients with resectable, non-small cell lung cancer with switch to chemotherapy alternative in non-responders (NEOSCAN). Available from: http://clinicaltrials.gov/show/ NCT01443078
59. Customized neoadjuvant versus standard chemotherapy in NSCLC patients with resectablestage IIIA (N2) disease (CONTEST). Available from: http://clinicaltrials.gov/ct2/show/NCT01784549
60. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007;13(2 Pt 1):515-22
61. Xu Y, Ma S, Ji Y, et al. Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): preliminary results of a phase II study. Lun Cancer 2011;72(3):327-32
62. Choy H, Schwartzberg LS, Dakhil SR, et al. Phase II study of pemetrexed (P) plus carboplatin (Cb) or cisplatin (C) with concurrent radiation therapy followed by pemetrexed consolidation in patients (pts) with favorable-prognosis inoperable stage IIIA/B non-small cell lung cancer (NSCLC). J Clin Oncol 2012;30(Suppl):abstract 7002
63. Vokes EE, Senan S, Treat JA, et al. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10(3):193-8
64. Gridelli C, Kaukel E, Gregorc V, et al. Single agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. J Thorac Oncol 2007;2(3):221-9
65. Gridelli C, Brodowicz T, Langer CJ, et al. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2012;13(5):340-6
66. Gervais R, Robinet G, Clément-Duchêne C, et al. Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Lung Cancer 2013;Epub ahead of print
67. Tamiya A, Tamiya M, Shiroyama T, et al. Dose escalation study of carboplatin-pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer. Ann Oncol 2013;24(3):980-5
68. Lilembaum R, Zukin M, Rodriguez-Pereira J, et al. A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of J Clin Oncol 2012;30(Suppl):abstract 7506
69. Giuliani G, Grossi F, De Marinis F, Walzer S. Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 2010;69(Suppl 1):S11-17
70. Ahn MJ, Tsai CM, Hsia TC, et al. Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan. Asia Pac J Clin Oncol 2011;7(Suppl 2):22-33
71. Davey P, Kanivets Y, Barraclough H, et al. Cost analysis, safety, and efficacy of pemetrexed/cisplatin compared with bevacizumab/gemcitabine/cisplatin in patients with previously untreated advanced non-squamous NSCLC in Russia. Value Health 2011;14(3):A161
72. De Marinis F, Grossi F. Clinical evidence for second-and third-line treatment options in advanced non-small cell lung cancer. Oncologist 2008;13(Suppl 1):14-20
73. Li M, Zhang Q, Fu P, et al. Pemetrexed plus platinum as the first-line treatment option for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS ONE 2012;7(5):e37229
74. Socinski MA, Raju RN, Stinchcombe T, et al. Randomized, phase II trial of pemetrexed and carboplatin with or without enzastaurin versus docetaxel and carboplatin as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5(12):1963-9
75. Al-Saleh K, Quinton C, Ellis PM, et al. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol 2012;19(1):e9-e15
76. De Boer RH, Arrieta O ́ , Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29(8):1067-74
77. Schiller JH, von Pawel J, Schütt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2010;5(12):1977-85
78. Chiappori A, Bepler G, Barlesi F, et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010;5(3):369-75
79. Scagliotti GV, Germonpré P, Bosquée L, et al. A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 2010;68(3):420-6
80. Qi WX, Tang LN, He AN, et al. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol 2012;138(5):745-51
81. Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. Lung Cancer 2011;74(1):132-8
82. Wang X, Wang Y, Wang Y, et al. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci 2013;20:5
83. Grossi F, Gridelli C, Aita M, De Marinis F. Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Crit Rev Oncol Hematol 2008;67(1):16-26
84. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44